Glenmark Pharmaceuticals schedules investor meetings in Singapore

Glenmark Pharmaceuticals Limited disclosed its schedule for analyst and institutional investor meetings, set to take place from September 11th to 12th, 2025. These physical one-on-one meetings will be held in Singapore, bringing together institutional investors and company representatives. The announcement, dated September 8, 2025, was made to comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company explicitly stated that no unpublished price sensitive information (UPSI) would be disclosed during these meetings. Glenmark Pharmaceuticals also noted that the schedule is subject to change based on exigencies from either the investor or the company's side. The intimation was sent to both BSE Ltd. and The National Stock Exchange of India Ltd.

Harish Kuber, company secretary & compliance officer, signed the intimation on behalf of Glenmark Pharmaceuticals Limited, reinforcing the company's commitment to transparency with its stakeholders. The company's registered office is located at B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026.